Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO‐D registry

AIM: Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real‐life registry, we describe the patterns of use, safety and fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobarro, David, Donoso‐Trenado, Víctor, Solé‐González, Eduard, Moliner‐Abós, Carlos, Garcia‐Pinilla, José Manuel, Lopez‐Fernandez, Silvia, Ruiz‐Bustillo, Sonia, Diez‐Lopez, Carles, Castrodeza, Javier, Méndez‐Fernández, Ana B., Vaqueriza‐Cubillo, David, Cobo‐Marcos, Marta, Tobar, Javier, Sagasti‐Aboitiz, Igor, Rodriguez, Miguel, Escolar, Vanessa, Abecia, Ana, Codina, Pau, Gómez‐Otero, Inés, Pastor, Francisco, Marzoa‐Rivas, Raquel, González‐Babarro, Eva, de Juan‐Baguda, Javier, Melendo‐Viu, María, de Frutos, Fernando, Gonzalez‐Costello, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053278/
https://www.ncbi.nlm.nih.gov/pubmed/36655614
http://dx.doi.org/10.1002/ehf2.14278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053278/
https://www.ncbi.nlm.nih.gov/pubmed/36655614
http://dx.doi.org/10.1002/ehf2.14278

Ejemplares similares